No.4
The stock price of Edesa Biotech Inc (NASDAQ: EDSA) – a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases – increased by over 60% pre-market. Investors are responding positively to the company announcing positive results from the Phase 2 part of an ongoing Phase 2/3 clinical study evaluating the company’s monoclonal antibody candidate, designated EB05, as a single-dose treatment for hospitalized COVID-19 patients.
low flowt
nice update
🤭今日は🈁かな⁉️
あとは$YANG💕💓💕
返信
投資の参考になりましたか？
